Literature DB >> 17218763

Inhibitors of cyclooxygenases: mechanisms, selectivity and uses.

R M Botting1.   

Abstract

The prostaglandins are lipid mediators, discovered in the 1930s by von Euler in Sweden and Goldblatt in the United Kingdom. They are made by the bifunctional enzyme, cyclooxygenase, which has both cyclooxygenase and peroxidase activities in the same molecule. Prostaglandins are involved in physiological functions such as protection of the stomach mucosa, aggregation of platelets and regulation of kidney function. They also have pathological functions such as their involvement in inflammation, fever and pain. Vane in 1971 elegantly showed that the pharmacological actions of aspirin and similar drugs were due to the inhibition of cyclooxygenase. Thus, aspirin-like drugs exert their anti-inflammatory, antipyretic and analgesic effects by inhibition of cyclooxygenase. In 1991, Simmons and his colleagues identified a second cyclooxygenase enzyme, designated cyclooxygenase-2, derived from a separate gene from cyclooxygenase-1. Cyclooxygenase-2 is upregulated by inflammatory mediators and forms prostaglandins which intensify the inflammatory response. Cyclooxygenase-1 is, therefore, a 'housekeeping' enzyme making prostaglandins, which are important for maintaining physiological functions and cyclooxygenase-2 makes prostaglandins which are important in inflammation. The discovery of cyclooxygenase-2 and the establishment of its structure led to the development of selective inhibitors of this enzyme, such as celecoxib and rofecoxib, with potent anti-inflammatory actions but with reduced gastrotoxic effects. A putative cyclooxygenase-3, has also been characterised and cloned. This enzyme is a product of the cyclooxygenase-1 gene, but retains intron 1 after transcription and translates into a cyclooxygenase enzyme with 34 additional amino acids. It is more sensitive to inhibition by paracetamol, aspirin and some other non-steroid anti-inflammatory drugs than cyclooxygenase-1 or cyclooxygenase-2. A cyclooxygenase enzyme induced in cultured cells by some non-steroid anti-inflammatory drugs is also more sensitive to inhibition by paracetamol than cyclooxygenase-2 induced by bacterial lipopolysaccharide.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17218763

Source DB:  PubMed          Journal:  J Physiol Pharmacol        ISSN: 0867-5910            Impact factor:   3.011


  32 in total

Review 1.  Oxycodone/paracetamol: a low-dose synergic combination useful in different types of pain.

Authors:  Antonio Gatti; Elisabetta Sabato; Anna Rita Di Paolo; Massimo Mammucari; Alessandro Fabrizio Sabato
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

2.  Intra-renal oxygenation in rat kidneys during water loading: effects of cyclooxygenase (COX) inhibition and nitric oxide (NO) donation.

Authors:  Lin Ji; Lu-Ping Li; Thomas Schnitzer; Hongyan Du; Pottumarthi V Prasad
Journal:  J Magn Reson Imaging       Date:  2010-08       Impact factor: 4.813

Review 3.  Lost but making progress--Where will new analgesic drugs come from?

Authors:  David Borsook; Richard Hargreaves; Chas Bountra; Frank Porreca
Journal:  Sci Transl Med       Date:  2014-08-13       Impact factor: 17.956

4.  Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues.

Authors:  Sai Prachetan Balguri; Goutham R Adelli; Soumyajit Majumdar
Journal:  Eur J Pharm Biopharm       Date:  2016-10-25       Impact factor: 5.571

5.  Enhanced analgesic effects of nefopam in combination with acetaminophen in rodents.

Authors:  Qian Li; Quankun Zhuang; Yaru Gu; Cailing Dai; Xiaoxiao Gao; Xiaomin Wang; Huimin Wen; Xin Li; Yuyang Zhang
Journal:  Biomed Rep       Date:  2017-12-18

6.  [Pediatric perioperative systemic pain therapy: Austrian interdisciplinary recommendations on pediatric perioperative pain management].

Authors:  B Messerer; G Grögl; W Stromer; W Jaksch
Journal:  Schmerz       Date:  2014-02       Impact factor: 1.107

Review 7.  Celecoxib: a review of its use in the management of arthritis and acute pain.

Authors:  James E Frampton; Gillian M Keating
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 8.  Different mechanisms in formation and prevention of indomethacin-induced gastric ulcers.

Authors:  Halis Suleyman; Abdulmecit Albayrak; Mehmet Bilici; Elif Cadirci; Zekai Halici
Journal:  Inflammation       Date:  2010-08       Impact factor: 4.092

9.  Influence of cyclodextrin complexation with NSAIDs on NSAID/cold stress-induced gastric ulceration in rats.

Authors:  Ibrahim A Alsarra; Mahrous O Ahmed; Fars K Alanazi; Kamal Eldin Hussein Eltahir; Abdulmalik M Alsheikh; Steven H Neau
Journal:  Int J Med Sci       Date:  2010-07-05       Impact factor: 3.738

Review 10.  Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis.

Authors:  Katherine F Croom; M Asif A Siddiqui
Journal:  Drugs       Date:  2009-07-30       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.